Contact
Please use this form to send email to PR contact of this press release:
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TO:
Please use this form to send email to PR contact of this press release:
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TO: